PDAPS | Prescription Drug Abuse Policy System


Papers in Peer-Reviewed Publications Citing PDAPS
  1. 1

    Abouk, R. et al. (2021).

    Does Marijuana Legalization Affect Work Capacity? Evidence from Workers’ Compensation Benefits

    NBER Working Paper, https://www.nber.org/papers/w28471

  2. 2

    Abouk, R., & Powell, D. (2021).

    Can electronic prescribing mandates reduce opioid-related overdoses?

    Economics & Human Biology, https://www.sciencedirect.com/science/article/pii/S1570677X21000241

  3. 3

    Bohler, R., Hodgkin, D., Kreiner, P., & Green, T. (2021).

    Predictors of US States' Adoption of Naloxone Access Laws, 2001-2017

    Drug and Alcohol Dependence, https://www.sciencedirect.com/science/article/abs/pii/S0376871621002672

  4. 4

    Elliot, J. et al. (2021).

    Naloxone Availability in Community Pharmacies

    Substance Abuse, Treatment, Prevention, and Policy (preprint), https://www.researchsquare.com/article/rs-340874/v1

  5. 5

    Farley, N. (2021).

    Medical Street Wisdom: A Community-based Study on the Precarity and Utility of Unapproved Opioid Overdose Reversal Techniques among Syringe Exchange Clientele

    University of California, Santa Barbara, https://escholarship.org/content/qt5j08q4jf/qt5j08q4jf.pdf

  6. 6

    Gottschalk, M. (2021).

    No Star State: What's Right and Wrong About Criminal Justice Reform in Texas

    Seattle Journal for Social Justice, https://digitalcommons.law.seattleu.edu/cgi/viewcontent.cgi?article=2067&context=sjsj

  7. 7

    Guggino, K. (2021).

    Are Prescription Drug Monitoring Programs Effective? An Analysis of the Impact of Prescription Drug Monitoring Programs (PDMPs) Operational Variation on Prescription Opioid Misuse and Abuse

    University of Maryland, Baltimore County, ProQuest Dissertations Publishing, https://www.proquest.com/openview/f7b53fe374ee3bc604adddc2de1c9371/1?pq-origsite=gscholar&cbl=18750&diss=y

  8. 8

    Guth D., & Zhang, S. (2021).

    Geographic Spillover Effects of Prescription Drug Monitoring Programs (PDMPs)

    N/A, https://arxiv.org/pdf/2107.04925.pdf

  9. 9

    Haas, E. (2021).

    Health and Social Services F-4 The Opioid Crisis

    Kansas Legislator Briefing Book 2019, http://www.kslegresearch.org/KLRD-web/Publications/BriefingBook/2019Briefs/F-4-TheOpioidCrisis.pdf

  10. 10

    Hamilton, L., Davis, C., Kravitz-Wirtz, N., Ponicki, W., & Cerdá, C. (2021).

    Good Samaritan laws and overdose mortality in the United States in the fentanyl era

    International Journal of Drug Policy, https://www.sciencedirect.com/science/article/abs/pii/S0955395921002000

  11. 11

    Hsu, G., & Kovács, B. (2021).

    Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study

    The BMJ, https://www.bmj.com/content/372/bmj.m4957

  12. 12

    Jayawardhana, J. (2021).

    Impact of Medicaid expansion on mental health and substance use related emergency department visits

    Substance Abuse, https://www.tandfonline.com/doi/abs/10.1080/08897077.2021.1941521

  13. 13

    Jayawardhana, J., & Fernandez, J. (2021).

    The associations of medical marijuana policies with opioid‐related health care utilization

    Health Services Research, https://onlinelibrary.wiley.com/doi/abs/10.1111/1475-6773.13632

  14. 14

    Kelly, B., Vuolo, M., & Frizzell., L (2021).

    Pediatric drug overdose mortality: contextual and policy effects for children under 12 years

    Pediatric Research, https://www.nature.com/articles/s41390-021-01567-7

  15. 15

    Kohan, L. (2021).

    Naloxone for the Pain Physician: What Do I Need to Know?

    ASRA, https://www.asra.com/the-asra-family/special-interest-groups/cannabis-in-acute-and-chronic-pain/cannabis-sig-article/asra-news/2021/02/01/naloxone-for-the-pain-physician-what-do-i-need-to-know

  16. 16

    Ma, S. (2021).

    The Effect of Monitoring Frequency on Prescription Opioids Overdose Death Rate

    Towards Data Science, https://towardsdatascience.com/the-effect-of-monitoring-frequency-on-prescription-opioids-overdose-death-rate-ccb4c9c741dd

  17. 17

    McGinty, E. et al. (2021).

    Protocol: mixed-methods study of how implementation of US state medical cannabis laws affects treatment of chronic non-cancer pain and adverse opioid outcomes

    Implementation Science, https://link.springer.com/article/10.1186/s13012-020-01071-2

  18. 18

    Metha, H., Kuo, Y., Raji, M., Westra, J., Boyd, C., Alexander, C., & Goodwin, J. (2021).

    State Variation in Chronic Opioid Use in Long-Term Care Nursing Home Residents

    Journal of the American Medical Directors Association, https://www.sciencedirect.com/science/article/abs/pii/S1525861021003947

  19. 19

    Meyerson, B., Moehling, T., Agley, J., Coles, H., & Phillips, J. (2021).

    Insufficient Access: Naloxone Availability to Laypeople in Arizona and Indiana, 2018

    Journal of Health Care for the Poor and Underserved, https://muse.jhu.edu/article/794650/summary

  20. 20

    Miller, S., Johnson, N., & Wherry, L. (2021).

    Medicaid and Mortality: New Evidence from Linked Survey and Administrative Data

    NBER Working Paper, https://www.nber.org/papers/w26081

  21. 21

    Parth S. et al. (2021).

    Availability of Naloxone in 2 Underserved Urban Communities in Georgia

    Journal of Public Health Management and Practice, https://journals.lww.com/jphmp/Fulltext/2021/05001/Availability_of_Naloxone_in_2_Underserved_Urban.14.aspx

  22. 22

    Pham, H. (2021).

    The role of insurance coverage in outpatient substance use disorder treatment referral, utilization, and outcomes

    Virginia Commonwealth University, https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=7860&context=etd

  23. 23

    Pham, T. (2021).

    Employment and Drug-Related Mortality

    Boise State University, https://scholarworks.boisestate.edu/cgi/viewcontent.cgi?article=2929&context=td

  24. 24

    Sabia, J., Dave, D., Alotaibi, F., & Rees, D. (2021).

    Is Recreational Marijuana a Gateway to Harder Drug Use and Crime?

    National Bureau of Economic Research, https://www.nber.org/system/files/working_papers/w29038/w29038.pdf

  25. 25

    Shakya, S. (2021).

    Three Essays on Health Economics and Policy Evaluation

    Graduate Theses, Dissertationsm and Problem Reports, West Virgina University, https://researchrepository.wvu.edu/cgi/viewcontent.cgi?article=8745&context=etd

  26. 26

    Taylor, J., Johnson, S., Cruz, R., Gray, J., Schiff, D., & Bagley, S. (2021).

    Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings

    Journal of General Internal Medicine, https://link.springer.com/article/10.1007/s11606-021-06904-4

  27. 27

    Wang, L. (2021).

    The complementarity of drug monitoring programs and health IT for reducing opioid-related mortality and morbidity

    Wiley, https://onlinelibrary.wiley.com/doi/pdf/10.1002/hec.4360

  28. 2020
  29. 1

    Adams, N. Gundlach, E. & Cheng C. (2020).

    An Analysis of State-Level Policies and Opioid Overdose Deaths.

    Western Journal of Nursing Research, https://journals.sagepub.com/doi/full/10.1177/0193945919897538

  30. 2

    Amaram-Davila, J., Mallipeddi, T., & Reddy, A. (2020).

    Opioid Prescribing with Take-Home Naloxone: Rationale and Recommendations.

    Current Anesthesiology Reports, https://link.springer.com/article/10.1007/s40140-020-00419-0

  31. 3

    Burris, S. (2020).

    Research on the Effects of Legal Health Interventions to Prevent Overdose: Too Often Too Little and Too Late

    American Journal of Public Health, https://doi.org/10.2105/AJPH.2020.305678

  32. 4

    Cerdá, M, et al. (2020).

    A Critical Review of the Social and Behavioral Contributions to the Overdose Epidemic

    Annual Review of Public Health, https://www.annualreviews.org/doi/abs/10.1146/annurev-publhealth-090419-102727

  33. 5

    Clemans-Cope, L., Epstein, M., & Winiski, E. (2020).

    Naloxone Products and Their Pricing in Medicaid, 2010-18: Trends for Opioid Overdose Reversal Drugs

    Urban Institute, https://www.urban.org/sites/default/files/publication/102769/naloxone-products-and-their-pricing-in-medicaid-2010-18.pdf

  34. 6

    Comartin, E., Nelson, V., Hambrick, N., Kubiak, S., Sightes, E., & Ray, B. (2020).

    Comparing For-Profit and Nonprofit Mental Health Services in County Jails

    The Jounral of Behavioral Health Services and Research, https://link.springer.com/article/10.1007/s11414-020-09733-1

  35. 7

    Darnell, A. (2020).

    Review of Scientific Evidence on Effects of Medical and Non-medical Marijuana Legalization on Public Health in the United States

    Report coordinated by the French Monitoring Centre for Drugs and Drug Addiction, https://en.ofdt.fr/BDD/publications/docs/ASTRACAN-Darnell-EN.pdf

  36. 8

    Davidson, P., Chakrabarti, P., & Marquesen, M. (2020).

    Impacts of mandated data collection on syringe distribution programs in the United States

    International Journal of Drug Policy, https://www.sciencedirect.com/science/article/abs/pii/S0955395920300669

  37. 9

    Dunsby, C. (2020).

    Naloxone Access and Opioid Use: A Theoretical Analysis

    Honors Theses, Colby College, https://digitalcommons.colby.edu/cgi/viewcontent.cgi?article=2014&context=honorstheses

  38. 10

    Earnshaw, V. (2020).

    Stigma and substance use disorders: A clinical, research, and advocacy agenda

    American Psychologist, https://psycnet.apa.org/record/2020-99903-024

  39. 11

    Ellyson, A., Grooms, J., & Ortega, A. (2020).

    Flipping the Script: Evaluating the Policy Effects and Restrictiveness of PDMPs on Opioid Prescribing Behavior.

    University of Washington, Working Paper, https://static1.squarespace.com/static/57c9d7602994ca1ac7d06b71/t/5efb7677b000c34cccb64ffb/1593538172758/Flipping_the_Script_Ellyson_et_al.pdf

  40. 12

    Everson, J. et al. (2020).

    Association of Electronic Prescribing of Controlled Substances With Opioid Prescribing Rates

    JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2774352

  41. 13

    Fine, D., Herzberg, D., & Wakerrman, S. (2020).

    Societal Biases, Institutional Discrimination, and Trends in Opioid Use in the USA.

    Journal of General Internal Medicine, https://link.springer.com/article/10.1007/s11606-020-05974-0

  42. 14

    Frizzell, L., Vuolo, M., & Kelly, B. (2020).

    State pain management clinic policies and county opioid prescribing: A fixed effects analysis.

    Drug & Alcohol Dependence, https://www-sciencedirect-com.libproxy.temple.edu/science/article/pii/S037687162030404X

  43. 15

    Ghimire, K. & Maclean, J. (2020).

    Medical marijuana and workers' compensation claiming

    Health Economics, https://onlinelibrary.wiley.com/doi/abs/10.1002/hec.3992

  44. 16

    Gupta, S., Nguyen, T., Freeman, P., & Simon, K. (2020).

    Competitive Effects of Federal and State Opioid Restrictions: Evidence from the Controlled Substance Laws

    National Bureau of Economic Research (NBER) Working Paper No. 27520, https://www.nber.org/papers/w27520

  45. 17

    Horowitz JR. et al. (2020).

    The importance of data source in prescription drug monitoring program research

    Health Services Research, https://onlinelibrary.wiley.com/doi/abs/10.1111/1475-6773.13548

  46. 18

    Jacksona, J. R., Harle, C., Silverman, R., Simon, K., & Menachemib, N. (2020).

    Characterizing variability in state-level regulations governing opioid treatment programs

    Journal of Substance Abuse Treatment, https://www.sciencedirect.com/science/article/abs/pii/S0740547219307081

  47. 19

    Jones, J., Campbell, A., Brandt, L., Castillo, F., Abbott, R., Comer, S. (2020).

    Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder

    Substance Abuse, https://www-tandfonline-com.libproxy.temple.edu/doi/full/10.1080/08897077.2020.1809607

  48. 20

    Kim, C., Lefkowitsb, C., Holschneiderc, C., Bixeld, K., & Pothurie, B. (2020).

    Managing opioid use in the acute surgical setting: A society of gynecologic oncology clinical practice statement

    Gynecologic Oncology, https://www.gynecologiconcology-online.net/article/S0090-8258(20)30068-8/fulltext

  49. 21

    Mackert, M., Pounders, K., Brown, L., Kirtz, S., Wagner, J., Ring, D., Hill, L., Wilcox, G., Murthy, D., Tierney, W., Innerarity, S., McGlone, M., Steiker, L., DeSalvo, K., Bernhardt J., & Pretorius, K. (2020).

    Development of a health communication campaign to promote the Texas prescription monitoring program

    Health Marketing Quarterly, https://www.tandfonline.com/doi/abs/10.1080/07359683.2020.1802967

  50. 22

    Magne, T. (2020).

    Essays on the Affordable Care Act Mandates and Their Effects on Labor Supply and Health Outcomes

    University of Delaware, ProQuest Dissertations Publishing, https://search-proquest-com.libproxy.temple.edu/docview/2456362783?pq-origsite=gscholar&fromopenview=true

  51. 23

    Mallinson, D., & Hannah, A. (2020).

    Policy and Political Learning: The Development of Medical Marijuana Policies in the States

    The Journal of Federalism, https://academic.oup.com/publius/article-abstract/doi/10.1093/publius/pjaa006/5819235

  52. 24

    McMichael, B. (2020).

    Occupational Licensing and the Opioid Crisis

    UC Davis Law Review, https://lawreview.law.ucdavis.edu/issues/54/2/articles/files/54-2_McMichael_color.pdf

  53. 25

    Moallef, S., & Hayashi, K. (2020).

    The effectiveness of drug-related Good Samaritan laws: A review of the literature

    International Journal of Drug Policy, https://www.sciencedirect.com/science/article/abs/pii/S0955395920301146

  54. 26

    Nguyen, J. et al. (2020).

    Availability of Naloxone at Rural Georgia Pharmacies, 2019

    JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760889

  55. 27

    Pauly, N., Goodin, A. (2020).

    Chapter 51: Health Policy and Pharmacy

    Remington: The Science and Practice of Pharmacy (23rd ed.), https://www.sciencedirect.com/science/article/pii/B9780128200070000490

  56. 28

    Schneider K. et al. (2020).

    Polysubstance use in rural West Virginia: Associations between latent classes of drug use, overdose, and take-home naloxone

    International Journal of Drug Policy, https://www.sciencedirect.com/science/article/pii/S095539591930355X

  57. 29

    Schuler, M., Griffin, B., Cerdá, M., McGinty, E., & Stuart, E. (2020).

    Methodological challenges and proposed solutions for evaluating opioid policy effectiveness

    Health Services and Outcomes Research Methodology, https://link.springer.com/article/10.1007/s10742-020-00228-2

  58. 30

    Shakya, S. (2020).

    County Level Assessment of Prescription Drug Monitoring Program and Opioid Prescription Rate

    John Chambers College of Business and Economics & Regional Research Institute (RRI), West Virginia University https://shishirshakya.github.io/files/Papers/County_Level_Assessment_of_Prescription_Drug_Monitoring_Program_and_Opioid_Prescription_Rate.pdf

  59. 31

    Sohn, M. et al. (2020).

    Association between state Medicaid expansion status and naloxone prescription dispensing

    Health Services Research, https://onlinelibrary.wiley.com/doi/full/10.1111/1475-6773.13266

  60. 32

    Tan de Bibiana, J., Miller, C., Pope, L., Stellin, S., Parsons, J., & Cloud, D. (2020).

    Changing Course in the Overdose Crisis: Moving from Punishment to Harm Reduction and Health

    Vera, Institute of Justice, https://www.vera.org/downloads/publications/changing-course-in-the-overdose-crisis.pdf

  61. 33

    Tibbitts, J., & Cowan, B. (2020).

    The Opioid Safety Initiative and Veteran Suicides

    Washington State University, School of Economic Sciences, http://ses.wsu.edu/wp-content/uploads/2020/10/OSI-JMP.pdf

  62. 34

    Toce, M., Michelson, K., & Hudgins, J. et al. (2020).

    Association of State-Level Opioid-Reduction Policies With Pediatric Opioid Poisoning

    JAMA Pediatrics, https://jamanetwork.com/journals/jamapediatrics/article-abstract/2768207

  63. 35

    Wang, Z. (2020).

    Applications of Data Science Methods in Discovering Opioid Prescribing Patterns and the Mechanisms Underlying Substance Use Initiation and Addiction

    Indiana University, ProQuest Dissertations Publishing, https://search.proquest.com/openview/24f780ba69eacefa6fe690798af6f36e/1?pq-origsite=gscholar&cbl=51922&diss=y

  64. 36

    Waskell EN, et al. (2020).

    The impact of medical school education on the opioid overdose crisis with concurrent training in naloxone administration and MAT

    Journal of Addictive Diseases, https://www.tandfonline.com/doi/abs/10.1080/10550887.2020.1762030

  65. 37

    Williams, N. (2020).

    Media Portrayals of Drug Use and Users

    Indiana University of Pennsylvania (Dissertation), https://search.proquest.com/openview/d80088c9c1735484c6d0dbb773b080e1/1?pq-origsite=gscholar&cbl=18750&diss=y

  66. 38

    Winkler, A., Tobin, K., Gicquelais, R., Owczarzak, J., & Latkin, C. (2020).

    “When You're Getting High… You Just Don't Want to Be Around Anybody.” A Qualitative Exploration of Reasons for Injecting Alone: Perspectives from Young People Who Inject Drugs

    Substance Use and Misuse, https://www.tandfonline.com/doi/abs/10.1080/10826084.2020.1790008

  67. 2019
  68. 1

    Allen, S.T., Hamilton White, R., O’Rourke, A., Grieb, S.M., Kilkenny, M.E., Sherman, S.G. (2019).

    Take-home naloxone possession among people who inject drugs in rural West Virginia.

    Drug and Alcohol Dependence, Vol. 204, November 1, 2019. https://doi.org/10.1016/j.drugalcdep.2019.107581

  69. 2

    Bach, P., Hartung, D. (2019).

    Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. 14:30.

    Addiction Science & Clinical Practice. 14:30. https://doi.org/10.1186/s13722-019-0158-0

  70. 3

    Cariveau, D., Fay, A.E., Baker, D., Fagan, E.B., Gilmore Wilson, C. (2019).

    Evaluation of a pharmacist-led naloxone coprescribing program in primary care.

    Journal of the American Pharmacists Association, Volume 0, Issue 0. https://doi.org/10.1016/j.japh.2019.07.012

  71. 4

    Chan, N.W., Burkhardt, J., Flyr, M. (2019).

    The Effects of Recreational Marijuana Legislation and Dispensing on Opioid Mortality.

    Econ Inq. doi:10.1111/ecin.12819.

  72. 5

    Chisholm-Burns, M.A., Spivey, C.A., Sherwin, E., Wheeler, J., Hohmeier, K. (2019).

    The opioid crisis: Origins, trends, policies, and the roles of pharmacists.

    American Journal of Health-System Pharmacy, 76(7), 424-435, doi: https://doi.org/10.1093/ajhp/zxy089

  73. 6

    Desai, R.J., Jin, Y., Franklin, P.D., Lee, Y.C., Bateman, B.T., Lii, J., Solomon, D.H., Katz, J.N., Kim, S.C. (2019).

    Association of Geography and Access to Health Care Providers with Long-Term Prescription Opioid Use in Medicare Patients with Severe Osteoarthritis: A Cohort Study.

    Arthritis & Rheumatology, 71:5, 712-721, May 2019. https://doi.org/10.1002/art.40834

  74. 7

    Diang L, Shi Y. (2019).

    The association between pain clinic laws and prescription opioid exposures: New evidence from multi-state comparisons.

    Drug and Alcohol Dependence, https://www.sciencedirect.com/science/article/pii/S0376871619305319

  75. 8

    Donohue, J.M., Kennedy, J.N., Seymour, C.W., Girard, T.D., Lo-Ciganic, W.H., Kim, C.H., Marroquin, O.C., Moyo, P., Chang, C.C.H., Angus, D.C. (2019).

    Patterns of opioid administration among opioid-naive inpatients and associations with postdischarge opioid use.

    Ann. Intern. Med. Published online June 18, 2019. doi:10.7326/M18-2864

  76. 9

    Fletcher, J., Molloy, M., Hart, A., Voskanyan, A., Sarin, R., & Ciottone, G. (2019).

    Evolution of United States Legislation to Facilitate Bystander Response to Opioid Overdose.

    Prehospital and Disaster Medicine, 34(S1), S130-S130. doi:10.1017/S1049023X19002826

  77. 10

    Frank, R.G., Fry, C.E. (2019).

    The Impact of Expanded Medicaid Eligibility on Access to Naloxone.

    Addiction. https://doi.org/10.1111/add.14634

  78. 11

    Fudin, J., Persico, A. L., Bettinger, J. J., & Wegrzyn, E. L. (2019).

    The state of naloxone: Access amid a public health crisis.

    Medicine Access @ Point of Care. https://doi.org/10.1177/2399202619847639

  79. 12

    Haas, E. (2019).

    Health and Social Services F-4 The Opioid Crisis

    Kansas Legislator Briefing Book 2019, http://www.kslegresearch.org/KLRD-web/Publications/BriefingBook/2019Briefs/F-4-TheOpioidCrisis.pdf

  80. 13

    Haffajee, R., French, C.A. (2019).

    Provider Perceptions of System-Level Opioid Prescribing in Addiction Treatment Policies.

    Current Opinion in Psychology 2019. doi: https://doi.org/10.016/j.copsyc.2019.01.018

  81. 14

    Hohmann, L. (2019).

    An untapped potential in addressing the opioid epidemic.

    Journal of the American Pharmacists Association 59, 625-627. https://www.japha.org/article/S1544-3191(19)30358-9/pdf

  82. 15

    Kravitz-Wirtz N. et al. (2019).

    Association of Medicaid Expansion With Opioid Overdose Mortality in the United States.

    JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2758476

  83. 16

    Lowenstein, M., Hossain, E., Yang, W., Grande, D., Perrone, J., Neuman, M.D., Ashburn, M., Delgado, M.K. (2019).

    Impact of a State Opioid Prescribing Limit and Electronic Medical Record Alert on Opioid Prescriptions: a Difference-in-Differences Analysis.

    J. Gen. Intern. Med. https://doi.org/10.1007/s11606-019-05302-1

  84. 17

    Martins, S.S., Ponicki, W., Smith, N., Rivera-Aguirre, A., Davis, C.D., Fink, D.S., Castillo-Carniglia, A., Henry, S.G., Marshall, B.D.L., Gruenewald, P., Cerda, M. (2019).

    Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.

    Int’l J. of Drug Policy, 74: 174-180. https://doi.org/10.1016/j.drugpo.2019.10.001

  85. 18

    Moyo, P., Simoni-Wastila, L., Griffin, B.A., Harrington, D., Alexander, G.C., Palumbo, F., & Onukwugha, E. (2019).

    Prescription drug monitoring programs: Assessing the association between “best practices” and opioid use in Medicare.

    Health Serv. Res. 2019; 00. 1-10. https://doi.org/10.1111/1475-6773.13197

  86. 19

    Ruhm, C. (2019).

    Drivers of the fatal drug epidemic.

    Journal of Health Economics, 64 (2019) 25-42. doi: https://doi.org/10.1016/j.healeco.2019.01.001

  87. 20

    Smart R., Kase C., Taylor E., Stein B. (2019).

    Strengths and Weaknesses of Existing Data Sources to Support Research to Address the Opioids Crisis.

    Preventive Medicine Reports, https://doi.org/10.1016/j.pmedr.2019.101015

  88. 21

    Smith, J.O., Malinowski, S.S., Ballou, J.M. (2019).

    Public perceptions of naloxone use in the outpatient setting.

    Mental Health Clinician: July 2019, Vol. 9, No. 4, pp. 275-279. https://doi.org/10.9740/mhc.2019.07.275

  89. 22

    Strang, J., McDonald, R., Campbell, G., Degenhardt, L., Nielsen, S., Ritter, A., & Dale, A. (2019).

    Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.

    Drugs, 1-24. https://doi.org/10.1007/s40265-019-01154

  90. 23

    Strickler, G.K., Zhang, K., Halpin, J.F., Bohnert, A.S.B., Baldwin, G.T., Kreiner, P.W. (2019).

    Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.

    Drug and Alcohol Dependence, 199, 1-9. https://doi.org/10.1016/j.drugalcdep.2019.02.010

  91. 24

    Whitmore, C.C., White, M.N., Buntin, M.B., Fry, C.E., Calamari, K., Patrick, S.W. (2019).

    State laws and policies to reduce opioid-related harm: A qualitative assessment of PDMPs and naloxone programs in ten U.S. States.

    Preventative Medicine Reports, 13, 249-255, March 2019. https://doi.org/10.1016/j.pmedr.2018.12.014

  92. 25

    Yarbrough, C.R., Abraham, A.J., Bagwell Adams, G. (2019).

    Relationship of county opioid epidemic severity to changes in access to substance use disorder treatment, 2009-2017.

    Psychiatric Services, Psychiatry Online. https://doi.org/10.1176/appi.ps.201900150

  93. 2018
  94. 1

    Alexandra, S., Fahad, K., Alina, B., Germaine, C., Christopher, G., & V., D. L. (2018).

    New York Physicians' Perspectives and Knowledge of the State Medical Marijuana Program.

    Cannabis and Cannabinoid Research, 3(1), 74-84. doi: 10.1089/can.2017.0046

  95. 2

    Bennett, A. S., Bell, A., Doe-Simkins, M., Elliott, L., Pouget, E., & Davis, C. (2018).

    From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA.

    Journal of Psychoactive Drugs, 1-7. doi: 10.1080/02791072.2018.1430409

  96. 3

    Buchmueller, T. C., & Carey, C. (2018).

    The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare.

    American Economic Journal: Economic Policy, 10(1), 77-112. doi: doi: 10.1257/pol.20160094

  97. 4

    Freeman, P. R., Hankosky, E. R., Lofwall, M. R., & Talbert, J. C. (2018).

    The changing landscape of naloxone availability in the United States, 2011 – 2017.

    Drug and Alcohol Dependence, 191, 361-364. doi: https://doi.org/10.1016/j.drugalcdep.2018.07.017

  98. 5

    Gertner, A. K., Domino, M. E., & Davis, C. S. (2018).

    Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid.

    Drug Alcohol Depend, 190, 37-41. doi: 10.1016/j.drugalcdep.2018.05.014

  99. 6

    Goldberg, S. A., Dworkis, D. A., Liao, V. T., Eyre, A. J., Albert, J., Fawcett, M. M., . . . Weiner, S. G. (2018).

    Feasibility of Bystander Administration of Public-Access Naloxone for Opioid Overdose.

    Prehospital Emergency Care, 1-7. doi: 10.1080/10903127.2018.1461284

  100. 7

    Huang, L. C. (2018).

    Opioid Overdoses: A Webliography.

    Journal of Consumer Health on the Internet, 22(1), 42-52. doi: 10.1080/15398285.2018.1415597

  101. 8

    McClellan, C., Lambdin, B. H., Ali, M. M., Mutter, R., Davis, C. S., Wheeler, E., . . . Kral, A. H. (2018).

    Opioid-overdose laws association with opioid use and overdose mortality.

    Addictive Behaviors, 86, 90-95. doi: https://doi.org/10.1016/j.addbeh.2018.03.014

  102. 9

    Pauly, N. J., Slavova, S., Delcher, C., Freeman, P. R., & Talbert, J. (2018).

    Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings.

    Drug and Alcohol Dependence, 184, 26-32. doi: https://doi.org/10.1016/j.drugalcdep.2017.12.002

  103. 10

    Xu, J., Davis, C. S., Cruz, M., & Lurie, P. (2018).

    State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies.

    Drug & Alcohol Dependence, 189, 37-41. doi: 10.1016/j.drugalcdep.2018.04.020

  104. 11

    Lambdin, B. H., Zibbell, J., Wheeler, E., & Kral, A. H. (2018).

    Identifying gaps in the implementation of naloxone programs for laypersons in the United States.

    International Journal of Drug Policy, 52, 52-55. doi: https://doi.org/10.1016/j.drugpo.2017.11.017

  105. 12

    W. Ling, V. Nadipelli, N. Ronquest, V. Albright, A. Aldridge, S. Learned, V. Mehra, C. Heidbreder,

    Remission from chronic opioid use—Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics. Concli (2018),


  106. 2017
  107. 1

    Burris, S. (2017).

    Theory and methods in comparative drug and alcohol policy research: Response to a review of the literature.

    International Journal of Drug Policy, 41, 126-131. doi: http://dx.doi.org/10.1016/j.drugpo.2016.11.011

  108. 2

    Compton, W. M., Volkow, N. D., & Lopez, M. F. (2017).

    Medical marijuana laws and cannabis use: Intersections of health and policy.

    JAMA Psychiatry, 74(6), 559-560. doi: 10.1001/jamapsychiatry.2017.0723

  109. 3

    Cushman, P. A., Liebschutz, J. M., Hodgkin, J. G., Shanahan, C. W., White, J. L., Hardesty, I., & Alford, D. P. (2017).

    What do providers want to know about opioid prescribing? A qualitative analysis of their questions.

    Substance Abuse, 38(2), 222-229. doi: 10.1080/08897077.2017.1296525

  110. 4

    Davis, C., & Carr, D. (2017).

    State legal innovations to encourage naloxone dispensing.

    Journal of the American Pharmacists Association, 57(2, Supplement), S180-S184. doi: https://doi.org/10.1016/j.japh.2016.11.007

  111. 5

    Klieger, S. B., Gutman, A., Allen, L., Pacula, R. L., Ibrahim, J. K., & Burris, S. (2017).

    Mapping medical marijuana: State laws regulating patients, product safety, supply chains and dispensaries, 2017.

    Addiction, n/a-n/a. doi: 10.1111/add.13910

  112. 6

    Lapham, G. T., Lee, A. K., Caldeiro, R. M., McCarty, D., Browne, K. C., Walker, D. D., . . . Bradley, K. A. (2017).

    Frequency of Cannabis Use Among Primary Care Patients in Washington State.

    The Journal of the American Board of Family Medicine, 30(6), 795-805. doi: 10.3122/jabfm.2017.06.170062

  113. 7

    Pardo, B. (2017).

    Do more robust prescription drug monitoring programs reduce prescription opioid overdose?

    Addiction, 112(10), 1773-1783. doi: 10.1111/add.13741

  114. 8

    Volkow, N. D., Compton, W. M., & Wargo, E. M. (2017).

    The risks of marijuana use during pregnancy.

    JAMA, 317(2), 129-130. doi: 10.1001/jama.2016.18612

  115. 2016
  116. 1

    Burris, S., Hitchcock, L., Ibrahim, J. K., Penn, M., & Ramanathan, T. (2016).

    Policy Surveillance: a Vital Public Health Practice Comes of Age.

    Journal of Health Politics, Policy & Law, 41(6), 1151-1167. doi: 10.1215/03616878-3665931

  117. 2

    Davis, C. S., Burris, S., Beletsky, L., & Binswanger, I. (2016).

    Co-prescribing naloxone does not increase liability risk.

    Substance Abuse, 37(4), 498-500. doi: 10.1080/08897077.2016.1238431

  118. 3

    Kitch, B. B., & Portela, R. C. (2016).

    Effective Use of Naloxone by Law Enforcement in Response to Multiple Opioid Overdoses.

    Prehospital Emergency Care, 20(2), 226-229. doi: 10.3109/10903127.2015.1076097

  119. 4

    Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016).

    Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates.

    Health Affairs, 35, 1045-1051. doi: 10.1377/hlthaff.2015.1496

  120. 2015
  121. 1

    Green, T. C., Bowman, S., Davis, C., Los, C., McHugh, K., & Friedmann, P. D. (2015).

    Discrepancies in Addressing Overdose Prevention through Prescription Monitoring Programs.

    Drug & Alcohol Dependence. doi: 10.1016/j.drugalcdep.2015.05.009

  122. 2

    Rutkow, L., Chang, H., Daubresse, M., Webster, D. W., Stuart, E. A., & Alexander, G. (2015).

    Effect of Florida’s prescription drug monitoring program and pill mill laws on opioid prescribing and use.

    JAMA Internal Medicine, 175(10), 1642-1649. doi: 10.1001/jamainternmed.2015.3931

  123. 3

    Rutkow, L., Turner, L., Lucas, E., Hwang, C., & Alexander, G. C. (2015).

    Most Primary Care Physicians Are Aware Of Prescription Drug Monitoring Programs, But Many Find The Data Difficult To Access.

    Health Affairs, 34(3), 484-492. doi: 10.1377/hlthaff.2014.1085

Law Review Articles Citing PDAPS
  1. 1

    Lawrence, M.J.B. (2019). Deputizing Family: Loved Ones as a Regulatory Tool in the "Drug War" and Beyond. 11 Ne. U. L. Rev. 195.

  2. 2

    Mahoney, M. (2018). The Global Opioid Crisis: Effective Laws to Fight Rising Overdose Fatalities Through Access to Naloxone. 35 Ariz. J. Int’l & Comp. L. 531.

  3. 3

    Seligman, J. (2018). Confronting a Crisis: An Appraisal of Legislation in Louisiana Combating the Opioid Epidemic. 93 Tul. L. Rev. 147.

  4. 4

    Millikan, J. (2019). Last Line of Defense: How Indiana Can Encourage Naloxone Availability During Its Opioid Crisis. 52 Indiana L. Rev. 329.

Other Literature Citing PDAPS
  1. 1

    2019 Indiana Professional Licensure Program: Targeted Series of CME for Controlled Substances Registration Renewal (2019).

    InforMed Continuing Medical Education. https://in.cme.edu/CourseMaterials/2019%20Indiana%20Professional%20Licensure%20Program~dmltbrvhulmg4llqvrwzjkor3-1-2019%204-42-59%20PM.pdf

  2. 2

    Ackerman, E., Frazier, A., Jackson, S., Raczkowski, E. (2019). An Overview of Michigan’s Effort in Combating the Opioid Epidemic. Issue Paper: Papers Examining Critical Issues Facing the Michigan Legislature.

    Senate Fiscal Agency. April 2019.

  3. 3

    Alpert AE et al. (2019). Origins of the Opioid Crisis and Its Enduring Impacts.

    NBER Working Paper, https://www.nber.org/papers/w26500

  4. 4

    Bivens, K.M. (2019). Reducing harm by designing discourse and digital tools for opioid users’ contexts: the Chicago Recovery Alliance’s community-based context of use and PwrdBy’s technology-based context of use.

    Newsletter: Communication Design Quarterly Review. 7:2. pp. 17-27. July 2019. doi: 10.1145/3358931.3358935.

  5. 5

    Brooks, K., Davis, T., Nguyen, K., Nguyen, N-D., Rahman, T., Villa, L. (2019). Evaluating Naloxone Access and Prescribing Requirements in the Opioid Epidemic across the United States.

    Poster: Southwestern Oklahoma State University, College of Pharmacy. March 2019. https://dc.swosu.edu/cgi/viewcontent.cgi?article=1031&context=cop_pp_articles

  6. 6

    Clemans-Cope, L., Allen, E.H., Basurto, L., Lawrence, D., Kenney, G.M. (2019). Research Report: Leveraging Medicaid to Address Opioid and Substance Use Disorders in Maine: Ten State Policy Options from an Expedited Review. Urban Institute.


  7. 7

    Crum J. (2019). The mediating impact of punitive heroin laws on Naloxone access laws and opioid overdose fatalities.

    The American Society of Criminology Conference, https://convention2.allacademic.com/one/asc/asc19/index.php?cmd=Online+Program+View+Paper&selected_paper_id=1546300&PHPSESSID=ckbgh3kojq9pga3494ke7sp757

  8. 8

    Erfanian, Elham Three Essays on Utilizing Spatial Econometrics in Natural Resource Economics related to Water, Health, and Energy. (2019)

    Graduate Theses, Dissertations, and Problem Reports. 4053. https://researchrepository.wvu.edu/etd/4053

  9. 9

    Guy, G.P. Jr., Haegerich, T.M., Evans, M.E., Losby, J.L., Young, R., Jones, C.M. (2019). Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.

    Morb. Mortal Wkly Rep. 2019; 68:679-686, doi: http://dx.doi.org/10.15585/mmwr.mm6831e1

  10. 10

    Issue Brief: Health Disparities Related to Opioid Misuse in Appalachia. (2019).

    In Creating a Culture of Health in Appalachia: Disparities and Bright Spots. East Tennessee State University and NORC at the University of Chicago. https://healthinappalachia.org/issue-briefs/opioid-misuse/

  11. 11

    Jackson, J.R. (2019). Examining the Variability In and Impact of State-Level Regulations of Opioid Treatment Programs.

    Dissertation, Richard M. Fairbanks, School of Public Health, Indiana University.

  12. 12

    Johnson S., Cohen Z. & Waqar T. (2019). Centralized pharmacy for validating prescription drugs.

    U.S. Patent Application No. 16/001,737, http://www.freepatentsonline.com/y2019/0378598.html

  13. 13

    Masterman, C.J. (2018). An Empirical Analysis of Policy Responses to the Opioid Epidemic.

    Dissertation, Vanderbilt University.

  14. 14

    Miller, A. (2019). Escaping Death: Naloxone’s Chemical Nature and Potential to Combat the Opioid Epidemic.

    Honors Theses, University of Nebraska-Lincoln, 102.

  15. 15

    Musse I. (2019). Employment Shocks and Demand for Pain Medication.

    Department of Economics, University of Illinois at Urbana-Champaign, https://economics.illinois.edu/sites/default/files/assoc-files/285/painkillers_imusse.pdf

  16. 16

    Newman, K. (2019). Study: Overdose Antidote Has Been in Short Supply at Philadelphia Pharmacies.

    U.S. News & World Report. June 7, 2019. https://www.usnews.com/news/healthiest-communities/articles/2019-06-07/overdose-antidote-has-been-in-short-supply-at-philadelphia-pharmacies

  17. 17

    Stancliff, S., Medley, B., Mathews, W. (2018). Harm Reduction: Caring for People Who Misuse Opioids. In M.T. Compton, & M. Manseau, (Eds.),

    The American Opioid Epidemic: From Patient Care to Public Health (pp. 337-360). Washington, DC: American Psychiatric Association Publishing.

Other Prescription Drug Abuse Policy Datasets
  1. 1

    Sonderegger Research Center, University of Wisconsin-Madison School of Pharmacy. State Laws and Other Regulatory Policies Related to Pain Care Map.

    Policy Surveillance Program: A LawAtlas Project. Valid through December 31, 2017. Available at: http://lawatlas.org/datasets/state-laws-and-other-regulatory-policies-related-to-pain-care-final

  2. 2

    Heins, S.E. Morphine Equivalent Daily Dose (MEDD) Policies Map.

    Policy Surveillance Program: A LawAtlas Project. Valid through June 1, 2017. Available at: http://lawatlas.org/datasets/morphine-equivalent-daily-dose-medd-policies